Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Keyhole limpet hemocyanin (KLH) is a large, multisubunit, oxygen-carrying metalloprotein derived from the marine mollusk *Megathura crenulata* (giant keyhole limpet). It is a highly immunogenic protein used primarily as an immune modulator and carrier protein in vaccine development and immunological research. KLH stimulates strong antigenic immune responses to haptens and weak antigens by acting as a carrier, making it valuable for generating antibodies in animals and humans. Clinically, it has been investigated as an adjuvant or component of vaccines for cancer immunotherapy—especially bladder carcinoma—and other conditions such as hepatitis C. Its mechanism involves enhancing both humoral and cellular immune responses without causing adverse reactions in humans[1][2][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on keyhole limpet hemocyanin.